(UroToday.com) The 2022 GU ASCO Annual meeting included a prostate cancer session highlighting work from Dr. Mark Boye and colleagues presenting results of their study assessing real-world health-related quality of life (HRQoL) and caregiver needs in patients with metastatic hormone-sensitive (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer is one of the most common cancers in men. When making treatment decisions, patient HRQoL and caregiver needs are important considerations, and as such, it is imperative to understand the impact that prostate cancer has on HRQoL. The aim of this study was to assess the impact of mHSPC and mCRPC on HRQoL and associated caregiver needs.
Real-world data were drawn from the Prostate Cancer Disease Specific Programme, a point-in-time survey conducted in the United States of America and Europe (France, Germany, Italy, Spain, and the United Kingdom) between January August 2020. Physicians completed patient record forms for their next 8 consecutively consulting adult metastatic prostate cancer patients (4 mHSPC/4 mCRPC). Eligible patients were invited to complete a voluntary patient self-reported form on caregiver need and HRQoL including EuroQol 5-dimension 5-level (EQ-5D-5L), EuroQol Visual Analogue Scale (EQ-VAS), Functional Assessment of Cancer Therapy – General/Prostate (FACT-G/P) and Brief Pain Inventory (BPI) questionnaires. Higher scores indicate better HRQoL and more pain.
There were 376 mHSPC and 331 mCRPC patients that completed patient self-reported forms. Demographics and clinical characteristics for mHSPC/mCRPC patients were: mean age 71.1/71.5 years, 77%/69% of patients had an ECOG performance status of 0-1, 82%/83% of patients were retired, and 42%/44% of patients had a caregiver.
At data collection, mean HRQoL scores for mHSPC/mCRPC patients were: 66.4/63.4 (EQ-VAS), 0.76/0.72 (EQ-5D-5L), 66.2/62.9 (FACT-G) and 94.6/90.2 (FACT-P). Patients with mHSPC had FACT-P social, emotional, functional and physical well-being subscale scores of 18.2, 14.7, 13.6 and 19.7, respectively. These scores were 17.7, 14.0, 12.7 and 18.5 in mCRPC patients, respectively:
Mean “worst pain” scores were mild (3.6/3.9 on BPI) for mHSPC/mCRPC patients:
In terms of both non-professional and professional caregivers, mHSPC/mCRPC patients reported a mean of 31.6/28.9 care hours/week. Most caregivers were partners/spouses (in 89% of mHSPC and 82% of mCRPC patients) providing a mean of 29.0 and 27.7 care hours/week, respectively. The median number of caregiver hours per week reported for patients with mHSPC (a) and mCRPC (b) is as follows:
Dr. Boye concluded his presentation of real-world HRQoL and caregiver needs in patients with mHSPC) and mCRPC with the following take-home messages:
- This study showed that HRQoL and well-being are impacted in both mHSPC and mCRPC patients and that there is a considerable time burden on caregivers
- Patients with mCRPC reported the lowest HRQoL scores and highest pain scores, suggesting that patients who are sicker may have greater disease burden
- These findings suggest an unmet need for HRQoL in patients with mHSPC and mCRPC, and also a need for greater caregiver support in these patients
Presented by: Mark Boye, Eli Lilly and Company, Adelphi Real World, Bollington, United Kingdom
Co-Authors: Amanda Ribbands, Andrea Leith, Emily Clayton, Jake Butcher, Sarah Rybowski
Written by: Zachary Klaassen, MD, MSc – Urologic Oncologist, Assistant Professor of Urology, Georgia Cancer Center, Augusta University/Medical College of Georgia, @zklaassen_md on Twitter during the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, Thursday Feb 17 – Saturday Feb 19, 2022